Shin Yu Seob, Park Jong Kwan
Department of Urology, Chonbuk National University Medical School, Jeonju 54907, Korea.
Research Institute of Clinical Medicine, Chonbuk National University, Jeonju, Korea.
J Clin Med. 2019 Feb 7;8(2):209. doi: 10.3390/jcm8020209.
The use of testosterone replacement therapy (TRT) for late-onset hypogonadism (LOH) is increasing every year; however, the literature shows that many men are using testosterone (T) without a clear indication. Previous studies have estimated that up to 25% of men who receive TRT do not have their T tested prior to initiation of the therapy. Given the growing concern and need for proper TRT, clinicians need evidence-based information that informs them on the optimal indication for TRT in LOH patients. The diagnosis of LOH requires the presence of characteristic signs and symptoms, in combination with decreased serum total testosterone (TT). Based on the recent guidelines by the International Society for the Study of Aging Male (ISSAM), the European Association of Urology (EAU), the European Society of Endocrinology (ESE), the European Academy of Andrology (EAA), and the American Association of Urology (AUA), a TT of 250⁻350 ng/dL is the proper threshold value to define low T. The optimal indication for TRT in LOH is the presence of signs and symptoms of hypogonadism, and low T without contraindications for TRT.
睾酮替代疗法(TRT)用于迟发性性腺功能减退(LOH)的情况逐年增加;然而,文献表明许多男性在没有明确指征的情况下使用睾酮(T)。先前的研究估计,接受TRT的男性中,高达25%在开始治疗前未进行T检测。鉴于对适当TRT的关注日益增加以及需求,临床医生需要基于证据的信息,以告知他们LOH患者TRT的最佳指征。LOH的诊断需要存在特征性体征和症状,同时血清总睾酮(TT)降低。根据国际老年男性研究学会(ISSAM)、欧洲泌尿外科学会(EAU)、欧洲内分泌学会(ESE)、欧洲男科学会(EAA)和美国泌尿外科学会(AUA)的最新指南,TT为250⁻350 ng/dL是定义低T的合适阈值。LOH患者TRT的最佳指征是存在性腺功能减退的体征和症状以及低T且无TRT的禁忌证。